Mayo study to evaluate a potential new treatment for epilepsy. Researchers want to learn if the investigational drug called perampanel is safe and can help people with partial seizures who are already taking seizure medications and the current seizure medications are not enough to control those seizures. Perampanel is being tested as a possible add-on drug for people with seizures who are taking other seizure medications.
NINDS sponsored study will examine the safety and effectiveness of infusing a chemical called muscimol into the brain to control seizures in patients with intractable epilepsy (frequent seizures that persist despite therapy). Muscimol, which is similar to a naturally occurring brain chemical called GABA, has been shown to reduce seizures in rats.
The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy - the most common form of epilepsy in kids - has established an evidence-based approach for initial drug therapy. Published March 4 in the New England Journal of Medicine*, data from the double-blind, randomized, comparative clinical trial fill a large information gap in the treatment of childhood absence epilepsy, also known as "petit mal" epilepsy. The research, which identifies important differences between drugs in seizure control and side effects, is expected to impact how physicians select and monitor initial therapy for children with the disorder and ultimately lead to improved outcomes.
Safety and Efficacy of Vanquix™ Auto-Injector (Diazepam Injection) for the Management of Selected, Refractory Patients With Epilepsy Who Require Intermittent Medical Intervention to Control Episodes of Acute Repetitive Seizures
Duke University Clinical trial and study to evaluate the safety, tolerability, and pharmacokinetics of the study drug Pregabalin in pediatric patients with partial onset seizures in addition to measuring how much pregabalin is in your child's blood and urine after he/she takes the study drug
Study to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.
Duke University and Multicenter, Open-label Study to Investigate the Safety,
Tolerability and Pharmacokinetics of Lacosamine (LCM) Oral Solution (syrup) as Adjunctive Therapy in Children with Partial Onset Seizures. This study is being done to test the safety of the study drug Lacosamide (LCM) syrup and how the body processes it.
Study being conducted to learn about the effects (both good and bad) of a brain stimulating device known as the External Responsive Neurostimulating System. This is an investigational device that was designed to detect seizure activity and give an electrical stimulation to the brain to try to stop it
NINDS sponsored study will investigate the role that a brain chemical called serotonin plays in seizures. Serotonin, present naturally in the brain, helps transmit signals between nerve cells. Glucose is a sugar that is the main fuel of the brain.
Study is designed to provide short term efficacy and safety data of TRI476 in children with inadequately-controlled partial seizures. The purpose of study is to confirm that TRI476 as adjunctive therapy is effective and safe.
Charliet Foundation - Offering Hope through the Ketogenic Diet. Founded in 1994 after twenty month old Charlie Abrahams, having endured multiple daily seizures, and failed every available anti-convulsant drug and one brain surgery, was cured of his epilepsy by the ketogenic diet at Johns Hopkins Hospital. The diet was undertaken despite resistance from the five pediatric neurologists he had seen.
Patients with epilepsy undergoing deep brain stimulation (DBS) have electroencephalograms (EEGs) recorded before and during their stimulation treatment. Subsequently we will be using computer-assisted analysis of the digitally-recorded EEG signals to assess the effects of DBS on the brain-wave frequency content and any abnormal seizure-like patterns that may be present.
Information and news on study funded by National Institute of Neurological Disorders and Stroke (NINDS) helps explain why newborn brain responds differently to anticonvulsant medications.
Mayo research study to determine if there are enough patients with hard to treat epilepsy that might qualify for a future study of a medical device that is being developed to treat epilepsy. Participants will not be testing the device during this study. The study doctor will be assessing seizure type(s) and determine how frequently they occur, and to verify if antiseizure medications can be held constant for a period of 12 weeks.
Group items tagged 
